Via Pharmaceuticals Company Insiders
| VIAP Stock | USD 0.0005 0.00 0.00% |
Via Pharmaceuticals employs about 6 people. The company is managed by 2 executives with a total tenure of roughly 14 years, averaging almost 7.0 years of service per executive, having 3.0 employees per reported executive. Discussion of Via Pharmaceuticals' management performance can provide insight into the enterprise performance.
Via Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (2.419) % which means that it has lost $2.419 on every $100 spent on assets. This is way below average. Via Pharmaceuticals' management efficiency ratios could be used to measure how well Via Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Via Pharmaceuticals' Return On Capital Employed is relatively stable compared to the past year. As of 12/25/2025, Return On Equity is likely to grow to 0.49, though Return On Tangible Assets are likely to grow to (20.98). As of 12/25/2025, Change To Liabilities is likely to grow to about 127.9 K, while Total Current Liabilities is likely to drop slightly above 11 M.As of 12/25/2025, Net Loss is likely to drop to about (11.6 M)
Via Pharmaceuticals Workforce Comparison
Via Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 465. Via Pharmaceuticals claims roughly 6.0 in number of employees contributing just under 2% to equities under Health Care industry.
Via Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Via Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Via Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Via Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Anderson Richard L over six months ago Acquisition by Anderson Richard L of 20000 shares of Via Pharmaceuticals at 2.38 subject to Rule 16b-3 | ||
Craves Fred B over six months ago Acquisition by Craves Fred B of 3671806 shares of Via Pharmaceuticals at 0.071 subject to Rule 16b-3 | ||
Flynn James E over six months ago Disposition of 259 shares by Flynn James E of Via Pharmaceuticals at 3.9799 subject to Rule 16b-3 | ||
Olukotun Adeoye Y over six months ago Acquisition by Olukotun Adeoye Y of 55758 shares of Via Pharmaceuticals at 0.03 subject to Rule 16b-3 |
Via Pharmaceuticals Notable Stakeholders
A Via Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Via Pharmaceuticals often face trade-offs trying to please all of them. Via Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Via Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| MD FACC | Chief Board | Profile | |
| Thomas Quertermous | Chief Board | Profile |
About Via Pharmaceuticals Management Performance
The success or failure of an entity such as Via Pharmaceuticals often depends on how effective the management is. Via Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Via management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Via management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (22.08) | (20.98) | |
| Return On Capital Employed | 0.29 | 0.31 | |
| Return On Assets | (22.08) | (20.98) | |
| Return On Equity | 0.47 | 0.49 |
Via Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Via Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Via Pharmaceuticals within its industry.Via Pharmaceuticals Manpower Efficiency
Return on Via Pharmaceuticals Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.6M | |
| Net Loss Per Executive | 4.8M |
Additional Tools for Via Stock Analysis
When running Via Pharmaceuticals' price analysis, check to measure Via Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Via Pharmaceuticals is operating at the current time. Most of Via Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Via Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Via Pharmaceuticals' price. Additionally, you may evaluate how the addition of Via Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.